Call Options

16 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2022

Feb 07, 2023

SELL
$9.89 - $12.7 $17,802 - $22,860
-1,800 Reduced 66.67%
900 $0
Q3 2022

Oct 25, 2022

BUY
$9.82 - $12.75 $26,514 - $34,425
2,700 New
2,700 $0
Q2 2022

Aug 04, 2022

SELL
$6.23 - $11.12 $66,038 - $117,871
-10,600 Closed
0 $0
Q1 2022

Apr 14, 2022

BUY
$7.89 - $12.48 $68,643 - $108,576
8,700 Added 457.89%
10,600 $5,000
Q3 2021

Oct 26, 2021

SELL
$8.74 - $11.84 $62,054 - $84,064
-7,100 Reduced 78.89%
1,900 $0
Q2 2021

Jul 19, 2021

SELL
$8.71 - $10.72 $152,425 - $187,600
-17,500 Reduced 66.04%
9,000 $1,000
Q1 2021

Apr 26, 2021

BUY
$9.2 - $23.86 $82,800 - $214,740
9,000 Added 51.43%
26,500 $4,000
Q4 2020

Jan 21, 2021

BUY
$13.47 - $24.89 $235,725 - $435,575
17,500 New
17,500 $67,000
Q3 2020

Oct 27, 2020

SELL
$12.89 - $15.89 $367,365 - $452,865
-28,500 Closed
0 $0
Q2 2020

Jul 22, 2020

BUY
$8.86 - $15.69 $252,509 - $447,165
28,500 New
28,500 $89,000
Q1 2019

May 10, 2019

SELL
$10.04 - $13.92 $16,063 - $22,272
-1,600 Closed
0 $0
Q3 2018

Nov 07, 2018

SELL
$11.6 - $16.54 $116,000 - $165,400
-10,000 Reduced 86.21%
1,600 $0
Q2 2018

Aug 10, 2018

SELL
$13.13 - $17.09 $6.59 Million - $8.58 Million
-501,800 Reduced 97.74%
11,600 $6,000
Q1 2018

May 11, 2018

BUY
$13.76 - $17.12 $5.85 Million - $7.27 Million
424,900 Added 480.11%
513,400 $215,000
Q4 2017

Jan 17, 2018

BUY
$12.51 - $16.24 $619,245 - $803,879
49,500 Added 126.92%
88,500 $124,000
Q3 2017

Oct 17, 2017

BUY
$11.74 - $15.78 $457,860 - $615,420
39,000
39,000 $198,000

Others Institutions Holding FOLD

About AMICUS THERAPEUTICS, INC.


  • Ticker FOLD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 280,497,984
  • Market Cap $2.7B
  • Description
  • Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...
More about FOLD
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.